Peripheral Vascular Diseases Clinical Trial
— RANGER-BTKOfficial title:
An Efficacy and Safety Study to Evaluate Ranger Drug-eluting Balloon for Below the Knee Angioplasty in Patients With Critical Limb Ischemia
Verified date | May 2018 |
Source | Assistance Publique - Hôpitaux de Paris |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Endovascular treatment of below the knee disease is a well-established therapy to improve
outcomes in patients with critical limb ischemia. Several large cohort studies demonstrated
the safety and the efficacy of percutaneous recanalization and angioplasty for distal vessel
disease. A successful recanalization of foot artery was related to a higher ulcer healing and
a reduction of major amputation. Moreover absence of revascularization in a patient with
critical limb ischemia is an independent risk factor for mortality. Despite the introduction
of new devices dedicated to below the knee vessel disease treatment, with the development of
guides and conical balloons, long term patency outcomes are still poor. Restenosis was
observed in more than two thirds of patients within 3 months after angioplasty of tibial
arteries with a high target lesions revascularization. These re-interventions are
characterized by a higher morbidity and mortality due to several comorbidities associated to
these patients. These data confirm the need to obtain more lasting results in order to
improve long-term outcomes of these patients.
Recently, the use of drug-eluting balloons (DEB) has revealed an increase in patency after
angioplasty of the femoral artery. On the contrary, results for BTK arteries angioplasty have
shown controversial results.
The purpose of this study is to evaluate the safety and the efficacy of the Ranger™ SL
paclitaxel coated balloon a model of drug eluting balloon in patients with critical limb
ischemia.
Status | Active, not recruiting |
Enrollment | 30 |
Est. completion date | November 2018 |
Est. primary completion date | May 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility |
Inclusion Criteria: General Inclusion Criteria : - Age =18 years and =85 years - Patient signed an approved consent form - Patient has documented chronic Critical Limb Ischemia (CLI) in the target limb prior to the study procedure with Rutherford Category 4, 5 or 6 - Menopausal or under contraception for women - Negative serum ß-HCG for women of childbearing age Angiographic Inclusion Criteria : - Single or multiple lesions with =70% diameter stenosis (DS) of different lengths in one or more main below the knee vessels - Intraluminal recanalization of the target lesion with successful traversal of the target lesion and placement of the guidewire into the distal true lumen - Reference vessel reference diameter comprised between 2 and 4 mm Exclusion Criteria: General non-inclusion criteria: - Patient with known hypersensitivity to paclitaxel - Patient unwilling or unlikely to comply with Follow-Up schedule - Life expectancy <1 year (investigator's appreciation) - Planned major index limb amputation - Pregnant or breast feeding women Angiographic exclusion criteria: - Significant (=50% DS) inflow lesion or occlusion in the ipsilateral iliac, superficial femoral or popliteal artery that cannot be treated successfully in the same session - Previously implanted stent in the target lesions(s) - Aneurysm in the target vessel - Acute thrombus in the target limb - Failure to cross the target lesion |
Country | Name | City | State |
---|---|---|---|
France | AP-HP - Hopital Europeen Georges-Pompidou Paris, France | Paris | Ile-de-France |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris | Boston Scientific Corporation |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety: Number of deaths and major amputations | Number of deaths and major amputations (any amputation above the knee) at 6 months after procedure | 6 months | |
Primary | Efficacy: Primary patency (no stenosis >50%) of the Target Lesion measured by Quantitative Vascular Angiography (QVA) | Primary patency (no stenosis >50%) of the Target Lesion measured by Quantitative Vascular Angiography (QVA) | 6 months | |
Secondary | Composite of all death and major amputation | Number of deaths and major amputations (any amputation above the knee) at 12 months after procedure | 12 months | |
Secondary | Number of SAEs | Procedure related or contributed total number of SAEs | 12 months | |
Secondary | Number of AEs | Procedure related or contributed total number of AEs | 12 months | |
Secondary | Late Lumen Loss (LLL) | Late Lumen Loss (LLL) of the Target Lesion measured by Quantitative Vascular Angiography (QVA) | 6 months | |
Secondary | Clinically driven Target Lesion Revascularization (TLR) | Clinically driven TLR is defined as any TLR of the target lesion associated with Deterioration of Rutherford Class and/or increase in size of pre-existing wounds and / or occurrence of a new wound(s) | 6 and 12 months | |
Secondary | Amputation Free Survival | 6 and 12 months | ||
Secondary | Rate of Wound Healing | 6 and 12 months | ||
Secondary | Quality of Life | Quality of Life assessed by EQ5D questionnaires | 6 and 12 months | |
Secondary | Ulcer diameter | Ulcer diameter in the target limb | 1, 6 and 12 months | |
Secondary | ABI (Ankle-Brachial Index) | ABI in the target limb | 1, 6 and 12 months | |
Secondary | Toe pressure | Toe pressure in the target limb | 1, 6 and 12 months | |
Secondary | Device success rates | Percentage of exact deployment of the device according to the instructions for use as documented with suitable imaging modalities | Through angioplasty completion | |
Secondary | Technical success rates | Percentage of successful vascular access, completion of the endovascular procedure and immediate morphological success with less or equal to 50% residual diameter reduction of the treated lesion on completion angiography | Through angioplasty completion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06032065 -
Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD)
|
Phase 3 | |
Completed |
NCT00536796 -
Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets
|
N/A | |
Completed |
NCT00371371 -
Intra-arterial Stem Cell Therapy for Patients With Chronic Limb Ischemia (CLI)
|
Phase 1/Phase 2 | |
Recruiting |
NCT00173602 -
The Burden of Peripheral Artery Occlusion Disease and Associated Factors in Peritoneal Dialysis Patients
|
N/A | |
Completed |
NCT00228384 -
GORE VIABAHN ENDOPROSTHESIS Peripheral Vascular Disease Study
|
Phase 4 | |
Completed |
NCT00163267 -
Mirror Trial - Follow-Up Management of Peripheral Arterial Intervention With Clopidogrel
|
Phase 2/Phase 3 | |
Completed |
NCT00106327 -
Improving Functioning in Peripheral Arterial Disease
|
N/A | |
Completed |
NCT00049907 -
Cardiac and Renal Disease Study (CARDS)
|
N/A | |
Completed |
NCT00000614 -
Prevention of Recurrent Venous Thromboembolism (PREVENT)
|
Phase 3 | |
Completed |
NCT00005392 -
Epidemiology of Venous Disease
|
N/A | |
Recruiting |
NCT05596760 -
Promoting Goals-of-Care Discussions for Patients With Memory Problems and Their Caregivers
|
N/A | |
Recruiting |
NCT00539266 -
Autologous Bone Marrow-derived Mononuclear Cells for Therapeutic Arteriogenesis in Patients With Limb Ischemia
|
Phase 2/Phase 3 | |
Completed |
NCT00541307 -
GORE VIABAHN Endoprosthesis With Heparin Bioactive Surface in the Treatment of SFA Obstructive Disease (VIPER)
|
N/A | |
Completed |
NCT00520312 -
Magnetic Resonance Imaging to Identify Characteristics of Plaque Build-Up in People With Peripheral Arterial Disease
|
N/A | |
Terminated |
NCT00504088 -
Plaque Removal Versus Open Bypass Surgery For Critical Limb Ischemia
|
Phase 4 | |
Completed |
NCT00533104 -
Cell Therapy in Chronic Limb Ischemia
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT05459818 -
Individual Patient Data Analysis of Viabahn for Peripheral Arterial Disease
|
||
Completed |
NCT03875846 -
Intraoperative Simultaneous Pressure Guided Revascularization Study
|
||
Active, not recruiting |
NCT05110677 -
Pilot Study of Topographic Imaging of the Calf Muscle in Patients With PAD Using 3D Reconstruction of MSOT Images
|
||
Completed |
NCT01014377 -
Effect of VascuActive Device on Foot Perfusion, Hemodynamics and Exercise Capacity in Patients With PVD & Limb Ischemia
|
N/A |